This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 4, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals has updated its corporate business & development information on OneMedDatabase, a division of OneMedPlace, a
New York-based healthcare research and business & development firm.
The profile is to serve as a portal for TPI in the development of partnership with U.S. as well as international pharmaceutical companies for the further growth expansion via TPI's in-depth coverage of pharmaceutical sales network in
China and TPI's upcoming macrolide antibiotic API business.
The updated profile of TPI along with an interview with the management can be found via the following link:
OneMedPlace (OMP), based in
New York, is a healthcare research company that manages a business development platform to help emerging healthcare and life sciences companies maximize their potentials. OMP provides companies and investors with efficient access to information about potential opportunities around the world through an integrated set of tools including:
OneMedDatabase: Over 8,000 companies and resources.
OneMedForum: a biannual business development and investment conferences in
San Francisco (January) and
New York City (June).
OneMedTV: Documentaries on promising companies and technologies and important healthcare events.
Sentinel: weekly e-newsletter tracking the major healthcare industrial trends.
For more information regarding OneMedPlace, please visit:
Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of
China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
For more information about TPI, please visit:
Safe Harbor Statement